Norris Perne & French LLP MI Reduces Holdings in Kenvue Inc. $KVUE

Norris Perne & French LLP MI reduced its position in Kenvue Inc. (NYSE:KVUE) by 25.1% in the 3rd quarter, Holdings Channel reports. The firm owned 531,799 shares of the company’s stock after selling 178,615 shares during the quarter. Norris Perne & French LLP MI’s holdings in Kenvue were worth $8,631,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Renaissance Capital LLC boosted its holdings in shares of Kenvue by 8.3% during the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after purchasing an additional 48,267 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Kenvue by 80.7% during the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after buying an additional 16,164 shares in the last quarter. Arlington Partners LLC acquired a new position in Kenvue during the second quarter worth $2,110,000. AG2R LA Mondiale Gestion D Actifs acquired a new position in Kenvue during the first quarter worth $1,725,000. Finally, Cornell Pochily Investment Advisors Inc. grew its holdings in Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after buying an additional 19,609 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Jeffrey C. Smith purchased 3,200,000 shares of the stock in a transaction dated Friday, December 12th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 0.17% of the stock is owned by company insiders.

Kenvue Trading Down 0.1%

NYSE KVUE opened at $17.20 on Monday. The firm’s 50-day moving average is $16.44 and its two-hundred day moving average is $18.69. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a market capitalization of $32.95 billion, a P/E ratio of 22.93 and a beta of 0.59.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the business earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. The Goldman Sachs Group cut their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, October 2nd. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $22.50 to $22.00 in a research note on Friday, September 26th. Jefferies Financial Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.23.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.